Bicocca Open Archive

Logo unimib boa
PIAZZA, ROCCO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.925
EU - Europa 7.930
AS - Asia 1.902
Continente sconosciuto - Info sul continente non disponibili 23
SA - Sud America 17
AF - Africa 11
OC - Oceania 5
Totale 24.813
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.688
DE - Germania 2.167
IT - Italia 2.005
IE - Irlanda 1.184
SE - Svezia 1.051
CN - Cina 1.021
UA - Ucraina 513
HK - Hong Kong 368
GB - Regno Unito 335
CA - Canada 236
FI - Finlandia 172
IN - India 128
TR - Turchia 112
FR - Francia 108
VN - Vietnam 104
DK - Danimarca 102
SG - Singapore 98
BE - Belgio 65
RU - Federazione Russa 56
NL - Olanda 32
AT - Austria 27
BG - Bulgaria 25
EU - Europa 22
IR - Iran 22
JP - Giappone 21
PL - Polonia 21
CH - Svizzera 18
KR - Corea 11
ES - Italia 9
CZ - Repubblica Ceca 8
BR - Brasile 7
GR - Grecia 7
RO - Romania 6
NO - Norvegia 5
LT - Lituania 4
SC - Seychelles 4
AU - Australia 3
CL - Cile 3
CO - Colombia 3
MK - Macedonia 3
MU - Mauritius 3
MY - Malesia 3
SA - Arabia Saudita 3
TH - Thailandia 3
BD - Bangladesh 2
EG - Egitto 2
NZ - Nuova Zelanda 2
PE - Perù 2
PT - Portogallo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
EC - Ecuador 1
EE - Estonia 1
ID - Indonesia 1
KW - Kuwait 1
MA - Marocco 1
MD - Moldavia 1
NG - Nigeria 1
PH - Filippine 1
PR - Porto Rico 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 24.813
Salva come PNG Salva come JPEG
Città #
Ann Arbor 4.898
Frankfurt am Main 1.514
Woodbridge 1.224
Dublin 1.155
Chandler 1.067
Fairfield 965
Milan 769
Wilmington 742
Houston 731
Ashburn 688
Jacksonville 527
Dearborn 507
New York 430
Seattle 395
Hong Kong 357
Cambridge 307
Princeton 302
Göttingen 205
Shanghai 165
Nanjing 162
Altamura 142
Beijing 141
Lawrence 120
Lachine 85
Boardman 81
San Diego 78
Fürstenwalde 71
Helsinki 70
Guangzhou 67
Toronto 67
Brussels 61
Fremont 58
Dong Ket 57
Andover 54
Nanchang 53
Rome 53
Shenyang 49
Lissone 48
Kocaeli 46
Ottawa 44
Monza 42
Hebei 41
Tianjin 39
Jiaxing 33
Carate Brianza 31
Los Angeles 31
Falls Church 29
Jinan 29
Kunming 28
London 28
Norwalk 26
Pune 26
Sacramento 25
Hangzhou 24
Changsha 22
Plovdiv 22
Sesto San Giovanni 22
Vienna 22
Huizen 21
Redmond 21
Edmonton 20
Lodz 20
Munich 20
Washington 19
Pavia 17
Turin 16
Hefei 15
Kiev 15
Mountain View 15
Bonndorf 14
Genoa 14
Leawood 12
Nürnberg 12
Meda 11
Monmouth Junction 11
Ningbo 11
Zhengzhou 11
Bologna 10
Lappeenranta 10
Zanjan 10
Buffalo 9
Cinisello Balsamo 9
Como 9
Kilburn 9
Singapore 9
Taiyuan 9
Verona 9
Auburn Hills 8
Delhi 8
San Mateo 8
University Park 8
Bergamo 7
Boston 7
Chicago 7
Corbetta 7
Daejeon 7
Desio 7
Duncan 7
Grafing 7
Lodi 7
Totale 19.558
Salva come PNG Salva come JPEG
Nome #
Longitudinal cancer evolution from single cells 429
Personalized therapy design for liquid tumors via optimal control theory 417
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 380
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 367
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 340
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 338
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 316
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 294
An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments 291
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 289
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 288
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 285
VERSO:A COMPREHENSIVE FRAMEWORK FOR THE INFERENCE OF ROBUST PHYLOGENIES AND THE QUANTIFICATION OF INTRA-HOST GENOMIC DIVERSITY OF VIRAL SAMPLES 278
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 277
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 271
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 267
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 259
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 258
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 258
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 258
Chronic myeloid leukemia: Second-line drugs of choice 256
Imatinib long term effects study: three years of follow-up and assessment 253
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 248
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 245
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 237
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 232
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 229
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 225
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 220
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 215
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 214
LACE: Inference of cancer evolution models from longitudinal single-cell sequencing data 211
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 210
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 201
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 201
VirMutSig: Discovery and assignment of viral mutational signatures from sequencing data 200
Hif1a: A putative modifier of hemochromatosis 194
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 193
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 193
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 191
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 189
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 186
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 185
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 185
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 185
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 184
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 183
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 181
Variant calling from scRNA-seq data allows the assessment of cellular identity in patient-derived cell lines 179
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 178
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 177
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 176
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 175
Reply to P. Laneuville et al 174
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 173
EXT 1 gene mutation induces chondrocyte cytoskeletal abnormalities and defective collagen expression in the exostoses 172
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 170
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 169
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 168
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 167
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 163
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 163
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 162
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 162
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 162
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 161
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 161
ABL INHIBITOR BMS354825 BINDING MODE IN ABELSON KINASE REVEALED BY MOLECULAR DOCKING STUDIES 157
Human chromosome 18 and acrocentrics: A dangerous liaison 156
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 154
Whole-Exome Sequencing Data - Identifying Somatic Mutations 154
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 153
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 152
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 152
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis 150
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 149
Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition 148
Whole-Exome Sequencing of 8 Atypical Chronic Myeloid Leukaemia Patients 148
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 147
Autoimmune hepatitis presenting as imatinib toxicity: description of a case and of therapeutic alternatives 146
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 145
First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis 143
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 141
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 139
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 139
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 138
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 137
How I treat newly diagnosed chronic myeloid leukemia in 2015 137
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 134
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 133
Identification of Novel Point Mutations in Splicing Sites by the Integration of Exome and RNA Sequencing Data in Myeloproliferative Diseases 133
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage 133
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 132
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 130
Read-through transcripts in normal human lung parenchyma are down-regulated in lung adenocarcinoma 128
In vitro proteoglycan sulfation derived from sulfhydryl compounds in sulfate transporter chondrodysplasias 127
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients 125
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 125
Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia 124
SNP MINING BY NANOGEN DEVICE: A SENSITIVE TOOL FOR THE IDENTIFICATION OF BCR/ABL MUTATIONS IN PH+ PATIENTS 123
Totale 19.850
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.062
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.062
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019553 0 0 0 0 0 0 0 0 0 0 253 300
2019/20204.108 406 289 280 276 347 460 621 319 384 330 288 108
2020/20214.809 192 177 451 460 419 455 513 448 453 463 342 436
2021/20223.341 313 301 354 244 233 295 225 183 183 227 295 488
2022/20235.119 604 1.360 515 520 400 631 90 242 313 100 183 161
2023/20243.812 162 187 223 260 506 1.076 753 151 308 145 41 0
Totale 25.966